{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:21:34Z","timestamp":1793467294205,"version":"4.5.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":894,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1093\/annonc\/mdx221","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T11:08:01Z","timestamp":1493982481000},"page":"iv84-iv99","source":"Crossref","is-referenced-by-count":372,"special_numbering":"S4","title":["EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours"],"prefix":"10.1016","volume":"28","author":[{"given":"E.","family":"Le Rhun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Brandsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx221_bb0010","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis\u2014the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0020","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","article-title":"Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations","volume":"129","author":"Lee","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx221_bb0030","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1524-4741.2012.01228.x","article-title":"Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer","volume":"18","author":"Lara-Medina","year":"2012","journal-title":"Breast J"},{"key":"10.1093\/annonc\/mdx221_bb0040","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1179\/1973947812Y.0000000034","article-title":"Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience","volume":"24","author":"Meattini","year":"2012","journal-title":"J Chemother"},{"key":"10.1093\/annonc\/mdx221_bb0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-011-0664-8","article-title":"Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment","volume":"106","author":"Kim","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0050","doi-asserted-by":"crossref","first-page":"408.","DOI":"10.1007\/s12032-012-0408-4","article-title":"Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival","volume":"30","author":"Niwi\u0144ska","year":"2013","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","article-title":"Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis","volume":"114","author":"Yust-Katz","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","article-title":"A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer","volume":"113","author":"Le Rhun","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clbc.2014.07.004","article-title":"Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy","volume":"15","author":"Niwi\u0144ska","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","article-title":"Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer","volume":"8","author":"Gwak","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0100","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1215\/15228517-2008-062","article-title":"Prognostic factors and outcomes in patients with leptomeningeal melanomatosis","volume":"10","author":"Harstad","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0105","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma","volume":"27","author":"Geukes Foppen","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0110","doi-asserted-by":"crossref","first-page":"17758.","DOI":"10.1038\/srep17758","article-title":"Surgical ventricular entry is a key risk factor for leptomeningeal metastasis of high grade gliomas","volume":"5","author":"Roelz","year":"2015","journal-title":"Sci Rep"},{"key":"10.1093\/annonc\/mdx221_bb0115","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3171\/2012.1.JNS111560","article-title":"Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection","volume":"116","author":"Ahn","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1093\/annonc\/mdx221_bb0120","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3171\/jns.1994.80.5.0834","article-title":"Ventricular entry during resection of malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination","volume":"80","author":"Elliott","year":"1994","journal-title":"J Neurosurg"},{"key":"10.1093\/annonc\/mdx221_bb0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/A:1005723801479","article-title":"Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication","volume":"32","author":"Norris","year":"1997","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jnnp.66.2.225","article-title":"Leptomeningeal metastasis after surgical resection of brain metastases","volume":"66","author":"van der Ree","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1093\/annonc\/mdx221_bb0135","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1227\/01.NEU.0000341535.53720.3E","article-title":"Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis","volume":"64","author":"Suki","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1093\/annonc\/mdx221_bb0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2015.11.022","article-title":"Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery","volume":"94","author":"Johnson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdx221_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx221_bb0150","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0155","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/ijc.21940","article-title":"Frequent EGFR mutations in brain metastases of lung adenocarcinoma","volume":"119","author":"Matsumoto","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0160","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0165","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/JTO.0000000000000029","article-title":"The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer","volume":"8","author":"Gainor","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0170","doi-asserted-by":"crossref","first-page":"pii E1074","DOI":"10.3390\/ijms17071074","article-title":"Molecular targeted therapies for the treatment of leptomeningeal carcinomatosis: current evidence and future directions","volume":"17","author":"Lee","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1093\/annonc\/mdx221_bb0175","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx221_bb0180","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","article-title":"Leptomeningeal metastases in the MRI era","volume":"74","author":"Clarke","year":"2010","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdx221_bb0185","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-010-0831-x","article-title":"Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis","volume":"136","author":"Oechsle","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bjc.6601953","article-title":"Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value","volume":"91","author":"Herrlinger","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0195","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-009-9940-2","article-title":"Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy","volume":"95","author":"Clatot","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0200","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","article-title":"Leptomeningeal metastasis: clinical experience of 519 cases","volume":"56","author":"Hyun","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","article-title":"Diffuse involvement of the leptomeninges by tumour\u2014a clinical and pathological study of 63 cases","volume":"56","author":"Boyle","year":"1980","journal-title":"Postgrad Med J"},{"key":"10.1093\/annonc\/mdx221_bb0210","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1002\/1097-0142(197606)37:6<2906::AID-CNCR2820370648>3.0.CO;2-D","article-title":"Meningeal carcinomatosis","volume":"37","author":"Gonzalez-Vitale","year":"1976","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0215","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","article-title":"Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?","volume":"51","author":"Kokkoris","year":"1983","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bpa.12241","article-title":"Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects","volume":"25","author":"K\u00fcsters-Vandevelde","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1093\/annonc\/mdx221_bb0225","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3346\/jkms.2014.29.8.1094","article-title":"Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors","volume":"29","author":"Kwon","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1093\/annonc\/mdx221_bb0230","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0235","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/neuonc\/nou089","article-title":"Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials","volume":"16","author":"Chamberlain","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ana.410380111","article-title":"Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis","volume":"38","author":"Freilich","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1093\/annonc\/mdx221_bb0245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1148\/radiology.217.1.r00oc3550","article-title":"Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging","volume":"217","author":"Singh","year":"2000","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mdx221_bb0250","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s004150050459","article-title":"The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis","volume":"246","author":"Straathof","year":"1999","journal-title":"J Neurol"},{"key":"10.1093\/annonc\/mdx221_bb0255","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-2141.2004.04853.x","article-title":"Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis\u2014a single centre experience","volume":"124","author":"Zeiser","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdx221_bb0260","first-page":"817","article-title":"MR imaging of leptomeningeal metastases: comparison of three sequences","volume":"23","author":"Singh","year":"2002","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1093\/annonc\/mdx221_bb0265","doi-asserted-by":"crossref","DOI":"10.1102\/1470-7330.2009.9004","article-title":"Meninges in cancer imaging","volume":"9","author":"Mahendru","year":"2009","journal-title":"Cancer Imaging"},{"key":"10.1093\/annonc\/mdx221_bb0270","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1634\/theoncologist.2011-0101","article-title":"Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches","volume":"16","author":"Lombardi","year":"2011","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdx221_bb0275","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0002-9343(82)90404-1","article-title":"Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography","volume":"73","author":"Grossman","year":"1982","journal-title":"Am J Med"},{"key":"10.1093\/annonc\/mdx221_bb0280","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","article-title":"Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status","volume":"75","author":"Glantz","year":"1995","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0285","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","article-title":"Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results","volume":"82","author":"Glantz","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0290","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.42.6.1239","article-title":"Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis","volume":"42","author":"Rogers","year":"1992","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdx221_bb0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0022-510X(94)90159-7","article-title":"A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid","volume":"121","author":"Dux","year":"1994","journal-title":"J Neurol Sci"},{"key":"10.1093\/annonc\/mdx221_bb0300","doi-asserted-by":"crossref","first-page":"e0122016.","DOI":"10.1371\/journal.pone.0122016","article-title":"Thinprep plus Papanicolaou stain method is more sensitive than cytospin-coupled Wright Giems stain method in cerebrospinal fluid cytology for diagnosis of leptomeningeal metastasis from solid tumors","volume":"10","author":"Pan","year":"2015","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx221_bb0305","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2008.17.7089","article-title":"Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin\u2019s lymphoma: improved sensitivity of flow cytometry","volume":"27","author":"Quijano","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0310","doi-asserted-by":"crossref","first-page":"752","DOI":"10.18632\/oncotarget.336","article-title":"Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases","volume":"2","author":"Patel","year":"2011","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx221_bb0315","doi-asserted-by":"crossref","first-page":"21.","DOI":"10.1186\/1472-6890-12-21","article-title":"Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis","volume":"12","author":"Le Rhun","year":"2012","journal-title":"BMC Clin Pathol"},{"key":"10.1093\/annonc\/mdx221_bb0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10549-015-3610-1","article-title":"Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer","volume":"154","author":"Lee","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx221_bb0325","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/nov273","article-title":"EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors","volume":"18","author":"Milojkovic Kerklaan","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0330","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3892\/ol.2015.3971","article-title":"Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer","volume":"11","author":"Ma","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1093\/annonc\/mdx221_bb0335","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10585-015-9716-3","article-title":"Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis","volume":"32","author":"Subir\u00e1","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1093\/annonc\/mdx221_bb0340","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.lungcan.2015.09.008","article-title":"CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis","volume":"90","author":"Tu","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0345","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gdata.2014.04.003","article-title":"Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors","volume":"2","author":"Magbanua","year":"2014","journal-title":"Genomics Data"},{"key":"10.1093\/annonc\/mdx221_bb0350","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","article-title":"Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases","volume":"128","author":"Li","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.resinv.2015.07.001","article-title":"Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure","volume":"54","author":"Sasaki","year":"2016","journal-title":"Respir Investig"},{"key":"10.1093\/annonc\/mdx221_bb0360","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/JTO.0b013e318219aaae","article-title":"Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis","volume":"6","author":"Shingyoji","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx221_bb0365","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jmoldx.2014.04.008","article-title":"Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases","volume":"16","author":"Yang","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1093\/annonc\/mdx221_bb0370","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-017-2452-6","article-title":"Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe","author":"Le Rhun","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0375","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1093\/annonc\/mdx221_bb0380","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0385","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0390","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1","article-title":"Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy","volume":"82","author":"Bokstein","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0395","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0400","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/COC.0b013e31815a43c4","article-title":"Extended survival in women with brain metastases from HER2 overexpressing breast cancer","volume":"31","author":"Church","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0405","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx221_bb0410","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0415","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx221_bb0420","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/sj.bjc.6605343","article-title":"Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies","volume":"101","author":"Toi","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0425","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(12)70432-1","article-title":"Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study","volume":"14","author":"Bachelot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0430","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdq434","article-title":"Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine","volume":"22","author":"Metro","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0435","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.bjc.6605586","article-title":"Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases\u2013the UK experience","volume":"102","author":"Sutherland","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0440","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10585-015-9740-3","article-title":"Activity of T-DM1 in Her2-positive breast cancer brain metastases","volume":"32","author":"Bartsch","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1093\/annonc\/mdx221_bb0445","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ctrc.2016.03.005","article-title":"Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: a case series","volume":"7","author":"Keith","year":"2016","journal-title":"Cancer Treat Commun"},{"key":"10.1093\/annonc\/mdx221_bb0450","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-016-3828-6","article-title":"Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases","volume":"157","author":"Jacot","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx221_bb0455","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clbc.2016.07.014","article-title":"Optimal management of leptomeningeal carcinomatosis in breast cancer patients\u2014a systematic review","volume":"16","author":"Dudani","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10549-009-0627-3","article-title":"Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue","volume":"123","author":"Park","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx221_bb0465","doi-asserted-by":"crossref","first-page":"299.","DOI":"10.1186\/s12885-015-1290-1","article-title":"A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis","volume":"15","author":"Wu","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0470","doi-asserted-by":"crossref","first-page":"e37229.","DOI":"10.1371\/journal.pone.0037229","article-title":"Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdx221_bb0475","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ctrv.2014.03.005","article-title":"Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases","volume":"40","author":"Zimmermann","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdx221_bb0480","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx221_bb0485","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx221_bb0490","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0495","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx221_bb0500","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.18632\/oncotarget.2886","article-title":"A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer","volume":"6","author":"Jackman","year":"2015","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdx221_bb0505","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10147-011-0256-9","article-title":"Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib","volume":"17","author":"Tetsumoto","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0510","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0515","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx221_bb0520","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","article-title":"Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer","volume":"70","author":"Togashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx221_bb0525","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2016.34.15_suppl.9002","article-title":"Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study","volume":"34","author":"Yang","year":"2016","journal-title":"J Clin. Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0530","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0535","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","article-title":"Targeting brain metastases in ALK-rearranged non-small-cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0540","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx221_bb0545","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx221_bb0550","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx221_bb0555","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx221_bb0560","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0565","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0570","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2340\/00015555-1654","article-title":"Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients","volume":"94","author":"Konstantinou","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1093\/annonc\/mdx221_bb0575","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/CMR.0b013e328352dbef","article-title":"Melanoma in the brain: biology and therapeutic options","volume":"22","author":"Gibney","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdx221_bb0580","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0585","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/CMR.0000000000000034","article-title":"Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial","volume":"24","author":"Fennira","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdx221_bb0590","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0595","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1005999228846","article-title":"Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?","volume":"38","author":"Siegal","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0600","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","article-title":"Systemic high-dose intravenous methotrexate for central nervous system metastases","volume":"78","author":"Lassman","year":"2006","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0605","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10072-015-2259-1","article-title":"Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series","volume":"36","author":"Chahal","year":"2015","journal-title":"Neurol Sci"},{"key":"10.1093\/annonc\/mdx221_bb0610","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1227\/00006123-198908000-00015","article-title":"Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody","volume":"25","author":"Benjamin","year":"1989","journal-title":"Neurosurgery"},{"key":"10.1093\/annonc\/mdx221_bb0615","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/80.15.1211","article-title":"Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study","volume":"80","author":"Burch","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx221_bb0620","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00689195","article-title":"Intrathecal administration of topotecan in nonhuman primates","volume":"36","author":"Blaney","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx221_bb0625","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/cncr.24921","article-title":"Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis","volume":"116","author":"Glantz","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0630","doi-asserted-by":"crossref","unstructured":"WRShapiro, MSchmid, MGlantz, JJ.MillerA randomized phase III\/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 2006; 24 (18 Suppl): 1528.","DOI":"10.1200\/jco.2006.24.18_suppl.1528"},{"key":"10.1093\/annonc\/mdx221_bb0635","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-015-1842-x","article-title":"Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients","volume":"124","author":"Zairi","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0640","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jocn.2015.11.005","article-title":"Stereotactic catheter placement for Ommaya reservoirs","volume":"27","author":"Kennedy","year":"2016","journal-title":"J Clin Neurosci"},{"key":"10.1093\/annonc\/mdx221_bb0645","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.wneu.2016.04.090","article-title":"Image guidance for placement of Ommaya reservoirs: comparison of fluoroscopy and frameless stereotactic navigation in 145 patients","volume":"93","author":"Morgenstern","year":"2016","journal-title":"World Neurosurg"},{"key":"10.1093\/annonc\/mdx221_bb0650","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1634\/theoncologist.2014-0199","article-title":"Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study","volume":"19","author":"Gwak","year":"2014","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdx221_bb0655","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","article-title":"Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. EasternCooperative Oncology Group","volume":"11","author":"Grossman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0660","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx221_bb0665","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchins","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0670","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/cncr.11449","article-title":"Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis","volume":"97","author":"Cole","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0675","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","article-title":"Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis","volume":"139","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdx221_bb0680","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.46.6.1674","article-title":"Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases","volume":"46","author":"Chamberlain","year":"1996","journal-title":"Neurology"},{"key":"10.1093\/annonc\/mdx221_bb0685","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1005982826121","article-title":"Radioisotope CSF flow studies in leptomeningeal metastases","volume":"38","author":"Chamberlain","year":"1998","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdx221_bb0690","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ijc.30214","article-title":"Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study","volume":"139","author":"Pan","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0695","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/cncr.24210","article-title":"Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology","volume":"115","author":"Chamberlain","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx221_bb0700","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S1470-2045(12)70266-8","article-title":"Epilepsy meets cancer: when, why, and what to do about it?","volume":"13","author":"Weller","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0705","first-page":"CD004424.","article-title":"Antiepileptic drugs for preventing seizures in people with brain tumors","author":"Tremont-Lukats","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdx221_bb0710","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clineuro.2014.01.023","article-title":"The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases","volume":"119","author":"Jung","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1093\/annonc\/mdx221_bb0715","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3892\/mco.2015.627","article-title":"Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: an analysis of 59 cases","volume":"3","author":"Nigim","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0720","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.mehy.2015.02.009","article-title":"Lumboperitoneal shunt for the treatment of leptomeningeal metastasis","volume":"84","author":"Zhang","year":"2015","journal-title":"Med Hypotheses"},{"key":"10.1093\/annonc\/mdx221_bb0725","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0269216316649128","article-title":"Palliative lumboperitoneal shunt for leptomeningeal metastasis-related hydrocephalus: a case series","volume":"31","author":"Yamashiro","year":"2017","journal-title":"Palliat Med"},{"key":"10.1093\/annonc\/mdx221_bb0730","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"EANO guidelines for palliative care in adult glioma patients","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx221_bb0735","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1468-1331.2004.00867.x","article-title":"Guidance for the preparation of neurological management guidelines by EFNS scientific task forces\u2014revised recommendations 2004","volume":"11","author":"Brainin","year":"2004","journal-title":"Eur J Neurol"},{"key":"10.1093\/annonc\/mdx221_bb0740","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419421492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419421492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/suppl_4\/iv84\/18564046\/mdx221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:40:36Z","timestamp":1624700436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419421492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":147,"alternative-id":["S0923753419421492"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx221","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}